# A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)

> **NCT01767688** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** MK-3102

## Key facts

- **NCT ID:** NCT01767688
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-16
- **Primary completion:** 2013-03-01
- **Final completion:** 2013-03-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767688, "A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01767688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*